Show simple item record

dc.contributor.authorCzypionka, Thomas
dc.contributor.authorIftekhar, Emil
dc.contributor.authorPrainsack, Barbara
dc.contributor.authorPriesemann, Viola
dc.contributor.authorBauer, Simon
dc.contributor.authorCalero Valdez, Andre
dc.contributor.authorCuschieri, Sarah
dc.contributor.authorGlaab, Enrico
dc.contributor.authorGrill, Eva
dc.contributor.authorKrutzinna, Jenny
dc.contributor.authorLionis, Christos
dc.contributor.authorMachado, Helena
dc.contributor.authorMartins, Carlos
dc.contributor.authorPavlakis, George
dc.contributor.authorPerc, Matjaz
dc.contributor.authorPetelos, Elena
dc.contributor.authorPickersgill, Martyn
dc.contributor.authorSkupin, Alexander
dc.contributor.authorSchernhammer, Eva
dc.contributor.authorSzczurek, Ewa
dc.contributor.authorTsiodras, Sotirios
dc.contributor.authorWilleit, Peter
dc.contributor.authorWilmes, Paul
dc.date.accessioned2023-03-29T13:21:56Z
dc.date.available2023-03-29T13:21:56Z
dc.date.created2022-01-11T15:06:16Z
dc.date.issued2022
dc.identifier.issn2666-7762
dc.identifier.urihttps://hdl.handle.net/11250/3060951
dc.description.abstractIn the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.urihttps://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00280-5/fulltext
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe benefits, costs and feasibility of a low incidence COVID-19 strategyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.source.articlenumber100294en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.lanepe.2021.100294
dc.identifier.cristin1978552
dc.source.journalThe Lancet Regional Health - Europeen_US
dc.relation.projectEC/H2020/724460en_US
dc.identifier.citationThe Lancet Regional Health - Europe. 2022, 13, 100294.en_US
dc.source.volume13en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal